Stockreport

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat [Seeking Alpha]

Immunome, Inc.  (IMNM) 
PDF Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "S [Read more]